Download PDF
Semin Thromb Hemost 2024; 50(01): 115-118
DOI: 10.1055/s-0043-1771269
Commentary

Russell Viper Venom: A Journey from the Bedside to the Bench and Back to the Bedside

Jecko Thachil 
1   Department of Haematology, Manchester University Hospitals, Manchester, United Kingdom
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Russell Viper Venom (RVV) is widely used as a diagnostic test for antiphospholipid syndrome (APS). But the history of how this venom came to be discovered is well known. Dr Patrick Russell is responsible for the identification of the venom during his work on snake bites in India while Dr Robert Macfarlane used it to staunch bleeding in persons with haemophilia. The ability to directly activate factor X led RVV to the laboratory diagnosis of APS. More recently, it has come back to clinical world with a potential for an engineered factor X activator from RVV to be used in the treatment of haemophilia.

Keywords

Russel Viper Venom - snake bite casualties - hemophilia


Publication History

Article published online:
28 July 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Hawgood BJ. The life and viper of Dr Patrick Russell MD FRS (1727-1805): physician and naturalist. Toxicon 1994; 32 (11) 1295-1304
    CrossrefPubMedGoogle Scholar
  • 2 Hawgood BJ. Rosemary Biggs MD FRCP (1912-2001) and Katharine Dormandy MD FRCP (1926-78): from laboratory to treatment and care of people with haemophilia. J Med Biogr 2013; 21 (01) 41-48
    CrossrefPubMedGoogle Scholar
  • 3 Hawgood BJ. Alexander Russell (1715-1768) and Patrick Russell (1727-1805): physicians and natural historians of Aleppo. J Med Biogr 2001; 9 (01) 1-6
    CrossrefPubMedGoogle Scholar
  • 4 Wellcome Collection. Accessed June 6, 2023 at: https://wellcomecollection.org/works/ytu8w5nq
    PubMed
  • 5 Chakrabarti P. “Neither of meate nor drinke, but what the Doctor alloweth”: medicine amidst war and commerce in eighteenth-century Madras. Bull Hist Med 2006; 80 (01) 1-38
    CrossrefPubMedGoogle Scholar
  • 6 Raman R, Raman A, Ram Manohar P. The arsenic and mercury-containing Tanjore pills used in treating snake bites in the 18th century Madras Presidency. Curr Sci 2014; 106: 1759-1763
    PubMedGoogle Scholar
  • 7 An account of Indian serpents, collected on the coast of Coromandel: containing descriptions and drawings of each species, together with experiments and remarks on their several poisons. Accessed June 7, 2023 at: https://www.biodiversitylibrary.org/bibliography/114003
    PubMed
  • 8 Owen Jr CA. Historical account of tests of hemostasis. Am J Clin Pathol 1990; 93 (4, Suppl 1): S3-S8
    PubMedGoogle Scholar
  • 9 Douglas S. Coagulation history, Oxford 1951-53. Br J Haematol 1999; 107 (01) 22-32
    CrossrefPubMedGoogle Scholar
  • 10 Mellanby J. The coagulation of blood. J Physiol 1908; 38 (01) 28-112
    CrossrefPubMedGoogle Scholar
  • 11 Martin CJ. On some effects upon the blood produced by the injection of the venom of the Australian Black Snake (Pseudechis Porphyriacus). J Physiol 1893; 15 (04) 380-400
    CrossrefPubMedGoogle Scholar
  • 12 Mellanby J. The coagulation of blood: part II. The actions of snake venoms, peptone and leech extract. J Physiol 1909; 38 (06) 441-503
    CrossrefPubMedGoogle Scholar
  • 13 Eagle H. The coagulation of blood by snake venoms and its physiologic significance. J Exp Med 1937; 65 (05) 613-639
    CrossrefPubMedGoogle Scholar
  • 14 MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202: 498-499
    CrossrefPubMedGoogle Scholar
  • 15 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145 (3638): 1310-1312
    CrossrefPubMedGoogle Scholar
  • 16 Macfarlane RG. Russell's viper venom, 1934-64. Br J Haematol 1967; 13 (04) 437-451
    CrossrefPubMedGoogle Scholar
  • 17 Macfarlane RG, Barnett B. The haemostatic possibilities of snake-venom. Lancet 1934; 224: 985-987
    CrossrefPubMedGoogle Scholar
  • 18 Directions for using 'Stypven' Russell Viper Venom (not for injection). Accessed June 6, 2023 at: https://wellcomecollection.org/works/urrqg9by
    PubMed
  • 19 MacFarlane RG, Ash BJ. The activation and consumption of factor X in recalcified plasma. The effect of added factor VIII and Russell's Viper Venom. Br J Haematol 1964; 10: 217-224
    CrossrefPubMedGoogle Scholar
  • 20 Macfarlane RG, Trevan JW, Attwood AM. Participation of a fat soluble substance in coagulation of the blood. J Physiol 1941; 99: 7
    PubMedGoogle Scholar
  • 21 Macfarlane RG. Proceedings of the Association of Clinical Biochemists. 1964; 3: 61-137
    PubMedGoogle Scholar
  • 22 Quick AJ. The prothrombin in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 83
    PubMedGoogle Scholar
  • 23 MacFarlane RG. The coagulant action of Russell's viper venom; the use of antivenom in defining its reaction with a serum factor. Br J Haematol 1961; 7: 496-511
    CrossrefPubMedGoogle Scholar
  • 24 Esnouf MP, Williams WJ. The isolation and purification of a bovine-plasma protein which is a substrate for the coagulant fraction of Russell's-viper venom. Biochem J 1962; 84 (01) 62-71
    CrossrefPubMedGoogle Scholar
  • 25 Shapiro SS, Thiagarajan P, De Marco L. Mechanism of action of the lupus anticoagulant. Ann N Y Acad Sci 1981; 370: 359-365
    CrossrefPubMedGoogle Scholar
  • 26 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48 (04) 499-509
    CrossrefPubMedGoogle Scholar
  • 27 Triplett DA, Brandt JT, Maas RL. The laboratory heterogeneity of lupus anticoagulants. Arch Pathol Lab Med 1985; 109 (10) 946-951
    PubMedGoogle Scholar
  • 28 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68 (04) 869-874
    CrossrefPubMedGoogle Scholar
  • 29 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
    CrossrefPubMedGoogle Scholar
  • 30 Liu W, Xue F, Fu R. et al. Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors. J Thromb Haemost 2023; 21 (06) 1453-1465
    CrossrefPubMedGoogle Scholar